论文部分内容阅读
目的：探讨采用帕利哌酮缓释片治疗非急性期精神分裂症的临床疗效及其安全性。方法随机选取郑州市第八人民医院2013年1月至2015年1月期间收治的非急性期精神分裂症患者43例，采用帕利哌酮缓释片进行治疗，对患者的临床治疗效果及其不良反应的发生情况进行观察记录，并对结果进行分析。结果41例患者经治疗后，其临床各项评分较治疗前均有显著下降，差异有统计学意义（P <0.05）；本研究14例患者出现药物不良反应，包括6例椎体外系不良反应，4例不能静坐，4例急性肌张力障碍。结论采用帕利哌酮缓释片治疗非急性期精神分裂症能够有效促进患者临床症状的改善，且其安全性可靠，可作为非急性期精神分裂症的有效治疗方案。“,”Objective To investigate the clinical efficacy and safety of paliperidone extended release tablets in the treatment of non-acute schizophrenia. Methods Randomly selected 43 cases of patients with schizophrenia in non-acute phase in the eighth people’s hospital of Zhengzhou from January 2013 to January 2015,using paliperidone extended release tablets for treatment,the incidence of clinical outcomes for patients and adverse reactions was observed and recorded,and the results were analyzed. Results The clinical scores of forty one patients after treatment were significantly decreased compared with that of before treatment,and the difference was significant(P < 0. 05). In this study,a total of 14 patients experienced adverse drug reactions,including six cases of extrapyramidal adverse reactions,four cases unable to sit still, four cases of acute dystonia. Conclusions The use of paliperidone extended release tablets in the treatment of non-acute schizophrenia can effectively promote the improvement of the clinical symptoms of patients,and its safety and reliable can be used as an effective treatment of non-acute schizophrenia.